Institut Francais Du Pe'trole

K.u. Leuven Research & Development

Air Products and Chemicals, Inc.

Umicore Ag & Co Kg

Katholieke Universiteit Leuven

Other

Exxonmobil Chemical Patents Inc.

The Dow Chemical Company

Exxon Chemical Patents, Inc.

Imec

Universiteit Gent

Katholieke Universiteit Leuven, Ku Leuven R&d

Atrium Medical Corporation

Sud-Chemie Ag

Universiteit Antwerpen

Johan Adriaan Martens

Pierre A Jacobs

Eric Benazzi

Emmanuelle Guillon

Charles G Coe

Guy Van Den Mooter

Hong-Xin Li

Thomas R Gaffney

Frank-Walter Schuetze

Jan Van Humbeeck

Sreeprasanth Pulinthanathu Sree

Elke Jane June Verheyen

Yanliang Xiong

Stef Jules Peter Kerkhofs

Machteld Maria Mertens

Pierre Jacobs

Ivan De Scheerder

Randy Mellaerts

Dominicus A Van Oeffelen

Mathias H Steijns

Christine Eva Antonia Kirschhock

Sebastien Philippe Brigitte Kremer

Alexander Jan Maria Herman Eugeen Aerts

Jan Nuyens

Jihad Mohammed Dakka

Scott Jeffrey Weigel

Christian Marcilly

Johannes Petrus Verduijn

Wilfried Jozef Mortier

Nathalie Marchal-George

Marcel J G Janssen

Edward Jobson

Luc Roger Martens

Georges M K Mathys

James Edward MacDougall

Arno Tissler

Christophe Detavernier

Antonie Jan Bons

Francesca Iacopi

Georges Marie Karel Mathys

Geraldine Tosin

Lennart Cider

Roger Eijkhoudt

Jean-Max Tyburn

Paul Anthony Webley

James G Kempf

Davy Deduytsche

Hubert Verachtert

Frank-Walter Schütze

Sam Smet

Thomas J Remans

Michiel De Prins

Gaëlle Hastoy

Rudy Parton

Silvia Lenaerts

Raman Ravishankar

Caroline Aerts

Francis Taulelle

Pieter Leo Hendrik Verlooy

Eric Breynaert

Sylvie Deckers

Maria Dhondt

Yan Liang Xiong

Wim Souverijns

Gilbert Froment

Nathalie George Marchal

Sammy Verbruggen

Mohammadreza Khalesi

David Santi Riveros Galan

Patrick Augustijns

Andreas Jan Hoffmann

Zahra Shokribousjein

Leen Van Tendeloo

Salvador Eslava Fernandez

Pieter Verlooy

Christine Kirschhock

Gina Vanbutsele

Roger Vermeiren

Guy Derdelinckx

Igor V Mishin

Joris Franken

Raman Rayishankar

Christine Eva Antiona Kirschhock

Marion Claude

David Habermacher

Nielsen Willemarck

Christine Eva Kirschhock

Alexander Jan Aerts

Sebastien Philippe Kremer

Charles Gardner Coe

James Edward Macdougall

Natan Blommaerts

Marcel Goemans

Antonie J Bons

Wilfried J Mortier

Christine E A Kirschhock

A method of enhancing the nuclear spin polarization of target molecules () uses a hyperpolarized source material () that is co-confined with the target molecules () in a porous molecular matrix (). The matrix () may be a D4R-polysiloxane copolymer such as polyoligosiloxysilicone number two (PSS-2) that has recesses of an appropriate diameter. A source material (), such as parahydrogen, is transferred to the matrix () together with the target molecules (), and an external pressure is applied to force them into the recesses of the matrix (). The nano-confinement of the source material () and target molecules () together enables or enhances a transfer of spin polarization from the source material () to the target molecules (). When the target molecules () are removed from the matrix (), the enhanced spin polarization greatly enhances the signal strength of the target molecules () in any subsequent magnetic resonance measurement.

Nuclear spin hyperpolarization in a porous matrix

The present invention provides crystalline aluminosilicate zeolites having a maximum pore size of eight tetrahedral atoms, wherein the zeolite has a total proton content of less than 2 mmol per gram. The zeolite may comprise 0.1 to 10 wt.-% of at least one transition metal, calculated as the respective oxide and based on the total weight of the zeolite. It may furthermore comprise at least one alkali or alkaline earth metal in a concentration of 0 to 2 wt.-%, calculated as the respective metal and based on the total weight of the zeolite. The zeolites may be used for the removal of NOx from automotive combustion exhaust gases.

Stable small-pore zeolites

The present invention relates to crystalline aluminosilicate comprising a MOZ framework type material. The MOZ framework type material comprises between 0.1 and 12.5 wt-% of copper, calculated as CuO, and one or more alkali and alkaline earth metal cations in an amount of 0.3 to 9 wt.-%, calculated as pure metals. The process for making the copper containing MOZ type zeolites comprises a) preparing a first aqueous reaction mixture comprising a silica source and potassium hydroxide, b) preparing a second reaction mixture comprising an alumina source, potassium hydroxide and a structure-directing agent selected from N,N-1,4-dimethyl-1,4-diazabicyclo-[2.2.2]octane difluoride, dichloride, dibromide, diiodide or dihydroxide, c) combining the two aqueous reaction mixtures, d) aging the combined reaction mixtures, e) heating the combined reaction mixtures, e) recovering, washing and drying the zeolite obtained thereof, g) calcining the zeolite, f) introducing copper, and i) washing and drying the copper containing MOZ type zeolite. Furthermore, the present invention discloses a washcoat comprising the copper containing MOZ framework type material, an SCR catalyst comprising said copper containing MOZ framework type material, and an exhaust gas purification system containing said SCR catalyst.

Copper containing MOZ zeolite for selective NOx reduction catalysis

The present invention relates to crystalline zeolites with an ERI/CHA intergrowth framework type and to a process for making said zeolites. The ERI content of the zeolites ranges from 10 to 85 wt.-%, based on the total weight of ERI and CHA. The zeolites may further comprise 0.1 to 10 wt.-% copper, calculated as CuO, and one or more alkali and alkaline earth metal cations in an amount of 0.1 to 5 wt.-%, calculated as pure metals. The process for making the zeolites with an ERI/CAH intergrowth framework type comprises a) the preparation of a first aqueous reaction mixture comprising a zeolite of the faujasite framework type, Cu-TEPA and a base M(OH), b) the preparation of a second aqueous reaction mixture comprising a silica source, an alumina source, an alkali or alkaline earth metal chloride, bromide or hydroxide, a quaternary alkylammonium salt and hexamethonium bromide, c) combining the two reaction mixtures, and d) heating the combination of the two reaction mixtures to obtain a zeolite with an ERI/CHA intergrowth framework type. The ERI/CHA intergrowth zeolite may subsequently be calcined. The zeolites according to the present invention are suitable SCR catalysts.

Crystalline zeolites with ERI/CHA intergrowth framework type

The present invention relates to a process for the manufacture of a copper containing small-pore zeolite which comprises&#x22c5;preparing a reaction mixture comprising a zeolite of the faujasite framework type, Cu-tetraethylenepentamine (Cu-TEPA) and at least one compound M(OH)x, which does not comprise the tetraethylammonium cation and&#x22c5;heating the reaction mixture to form a copper containing small-pore zeolite.

One-pot synthesis of copper containing small-pore zeolites

The present invention relates to hydrophobic coating of hydrophilic bottles for carbonated beverages to prevent gushing, in particular to hydrophobic coating of the bottle neck of a glass bottle. The invention also relates to a method to apply such hydrophobic coating to the inner surface of the glass bottle neck.

Bottles with means to prevent gushing

An olefin oligomerization process comprises contacting an olefin feed with a catalyst composition. The catalyst composition includes a crystalline aluminosilicate having FAU, EMT or a combination of FAU and EMT framework type. The crystalline aluminosilicate has cobalt and at least one alkaline earth metal selected from calcium, barium, strontium and mixtures thereof within its intra-crystalline cages.

Olefin olegomerization process

The invention provides a controlled release delivery system comprising a bio-active compound and a matrix carrier, wherein said matrix carrier is an amorphous microporous non-fibrous silicon or titanium oxide being loaded with said bio-active compound and wherein the micropores of said matrix carrier have a mean size in the range of 0.4 to 2.0 nm.

Controlled release delivery system for bio-active agents

The present invention relates to the use of atomic layer deposition (ALD) techniques to enhance the acid catalytic activity of nanoporous materials.

Enhancing catalytic activity of nanoporous materials

A coated implantable medical device is described, wherein the coating comprises a coating matrix and particles of one or more molecular sieves, preferably zeolite of zeogrid particles, optionally loaded with one or more bioactive agents. The coating matrix itself can function as a second drug-carrying interface. The coating comprising the molecular sieve material has an excellent biocompatibility and allows suitable drug delivery into the body of an animal, preferably a mammal and most preferably a human.

Biocompatible coating of medical devices

The invention relates to an intraluminal device, in particular an intraluminal prosthesis, shunt, catheter or local drug delivery device. In order to increase the bio-compatibility of this device, it is provided with at least one coating. The coating contains a therapeutic agent which is comprised in a matrix that sticks to the intraluminal device. Instead of being formed by a little bio-compatible polymer, the matrix is formed by a bio-compatible oil or fat, such as cod-liver oil or olive oil. Preferably, the bio-compatible oil or fat further comprises alfa-tocopherol.

Intraluminal device with a coating containing synthetic fish oil and a therapeutic agent

The invention describes a new class of crystalline silica material having two levels of porosity and structural order. At the first level, building units are nanoslabs of uniform size having zeolite framework. At the second structural level, nanoslabs are assembled, e.g. linked through their corners, edges or faces following patterns imposed by interaction with cationic surfactant or triblock copolymer molecules. After evacuation of these molecules, microporosity is obtained inside the nanoslabs, and a precise mesoporosity between the nanoslabs depending on the tiling pattern of the zeolite nanoslabs, as evidenced by X-ray diffraction. These materials are useful for the fixation of biologically active species, such as poorly soluble drugs.

Crystalline mesoporous oxide based materials useful for the fixation and controlled release of drugs

A process for the release of a biologically active species comprising the steps of:

Process for release of biologically active species from mesoporous oxide systems

The invention describes a new class of crystalline silica material having two levels or porosity and structural order. At the first level, building units are nanoslabs of uniform size having zeolite framework. At the second structural level, nanoslabs are assembled, e.g. linked through their corners, edges or faces following patterns imposed by interaction with cationic surfactant or triblock copolymer molecules. After evacuation of these molecules, microporosity is obtained inside the nanoslabs, and a precise mesoporosity between the nanoslabs depending on the tiling pattern of the zeolite nanoslabs, as evidenced by X-ray diffraction. These materials are useful for the fixation of biologically active species, such as poorly soluble drugs.

The invention provides a method for reducing the average size of biologically active compound particles or agglomerates suspended in a fluid by flowing one or more times said fluid having biologically active compound particles or agglomerates suspended therein through one or more magnetic fields to reduce the average size of a substantial portion of the biologically active compound particles or agglomerates by at least 25%. This method may be incorporated into a process for manufacturing a 10 biologically active compound formulation.

Particle size reduction of bioactive compounds

Growing community of inventors

Huldenberg, Belgium

Johan Adriaan Martens